The biology and clinical behaviour of kidney cancer -the most common malignancy seen in nephrology practiceis generally missing from the education of nephrologists. This state of affairs is all the more puzzling because of the interesting biology of kidney cancer and the opportunities for cutting-edge research. The field of onco nephrology has now been recognized by the nephrology community, but the main focus is on the renal responses and adverse events that occur as a result of the treatment of non-renal malignancies, rather than on kidney cancer. With this Comment, we hope to promote the concept that nephrologists should be aware of the biology of renal cell carcinoma (RCC) and understand the effects of its presence in the setting of chronic kidney disease (CKD) and of its treatment on the incidence and progression of CKD.
RCC in patients with kidney disease
Patients with CKD have a markedly high incidence of RCC. In particular, the risk of RCC among patients with end-stage renal disease (ESRD) is 100-fold greater than that of the general population, resulting in an incidence of up to 7%, which has been attributed to the high burden of acquired cystic kidney disease (ACKD) in patients on dialysis. Shared risk factors for RCC and CKD, including hypertension and diabetes mellitus, seem not only to contribute to CKD progression but also to promote an inflammatory milieu that is conducive to cancer induction. The risk of RCC might also be related to glomerular filtration rate (GFR) as this risk seems to increase with CKD stage among patients who are not on dialysis 1 . Albuminuria, an early presentation of a variety of renal diseases, has also been linked to RCC.
The association of RCC with poor kidney function was elegantly demonstrated in transplant recipients, among whom the incidence of RCC rose with graft failure and fell with re-transplantation 2 . Given these compelling data, the question arises as to whether nephrologists should screen for renal cancers in the CKD and ESRD populations. At present, routine screening of patients on dialysis is not regularly performed. Current practice is supported by an analysis that showed no clear survival benefit of ACKD screening in the ESRD population 3 . In our opinion, however, yearly screening with computed tomography for young patients with ESRD, in whom the benefits of RCC treatment would outweigh the risks of surgery, would be prudent. Screening of transplant candidates for RCC is more widely accepted, even though transplant recipients who develop RCC have a more favourable prognosis than their dialysisdependent peers or the general population. The issue of screening for kidney cancer remains controversial and requires the attention of nephrologists as well as further deliberations in the light of continually accruing data.
Management of RCC
Currently, the urological community, with oncological consultation, takes primary responsibility for the management of small renal masses. Nephrology involvement is not routine and is often deferred unless complications of AKI or CKD have occurred. The delay in nephrology care is partially related to the lack of consultation but also due This guideline promotes a working relationship between nephrologists, pathologists, oncologists, radiologists and urologists, and emphasizes counselling, diagnosis and management that incorporates kidney disease assessment, GFR preservation and diagnosis of kidney pathology 4
. Nephrology referral is recommended for patients with CKD, particularly those who have diabetes mellitus or are expected to experience a decline in GFR after surgery. Independent of nephrology referral, the guidelines advocate for CKD risk assessment with preoperative screening to evaluate serum creatinine and proteinuria levels for CKD staging according to the KDIGO classification. Optimal blood pressure and glycaemic control as well as careful attention to medication regimens to minimize nephrotoxicity may help to reduce the risk of AKI.
The historical treatment of renal masses was total nephrectomy, often without first obtaining a biopsy sample to confirm malignancy. This approach occasionally led to unnecessary surgery and resulted in excessive morbidity and mortality, especially among elderly and extant patients with CKD. The current dogma in the urology community is to consider partial over radical nephrectomy in many cases, and the risk of tumour seeding with RCC biopsy has been largely debunked 2 . Surprisingly, the rate of AKI following nephrectomy increased from 2% to 10.4% over the past decade, possibly owing to an ageing population with a greater prevalence of comorbidities, including more advanced CKD 5 . As AKI can lead to CKD or contribute to CKD progression, minimization of AKI risk is particularly important in patients with loss of nephron mass.
In the EORTC randomized controlled trial, the incidence of moderate renal dysfunction (estimated (e)GFR 30 to <60 ml/min/1.73 m 2 ) following surgery for a small renal mass was significantly lower with partial nephrectomy than with radical nephrectomy 6 . The incidence of more advanced CKD (eGFR <30 ml/min/1.73 m 2 ) was also slightly lower following partial nephrectomy, but this difference was not statistically significant. Oncological survival was similar in both nephrectomy groups but the incidence of renal cancer-related deaths was low. The AUA guidelines, therefore, recommend prioritizing partial nephrectomy for small renal masses 5 . Partial nephrectomy is also recommended for patients with comorbid diseases that are thought to affect kidney function, such as diabetes mellitus, severe hypertension, recurrent urolithiasis and morbid obesity 4 . Non-surgical, nephron-sparing procedures including thermal ablation offer greater GFR preservation for individuals with high surgical risk. Active surveillance has similar oncologic outcomes to nephrectomy and is associated with lower CKD risk in select groups, particularly in the elderly population 2 .
Future perspectives
The traditional lack of a role for nephrologists in the diagnosis and management of RCC is slowly changing concomitant with an awareness of onconephrology as a key part of the training and practice of a kidney physician. Given the complexity and intellectual challenge of RCC biology, the shared RCC and CKD risk factors and the adverse renal events that are associated with the treatment of RCC, the need for input of nephrologists into the teams that manage this disease is all the more pressing.
